METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY

用于肿瘤诊断和治疗的金属螯合单克隆抗体

• 批准号: 3838054
• 负责人: O A GANSOW
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3838054
• 关键词: Rauscher's virus; alpha radiation; antileukemic agent; antitumor antibody; beta radiation; bismuth; chelating agents; copper; cytolysis; cytotoxicity; disease /disorder model; laboratory mouse; monoclonal antibody; mouse leukemia; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiodiagnosis; neoplasm /cancer radionuclide therapy; radionuclide imaging /scanning; radionuclides; radiopharmacology; viral leukemia; yttrium

Tumor associated monoclonal antibodies are potential therapeutic agents as selective carriers of cytotoxic agents to malignant cells. We are testing this hypothesis in several animal model systems. The cytocidal agents being employed are various radionuclides. Their relative efficacy when conjugated to monoclonal antibodies is being assayed and compared to that of monoclonal antibodies alone or conjugated to toxins. The several radionuclides chosen for study span the range of radionuclidic properties available. Thus, Copper-67 is a weak, short range beta emitter. Yttrium-90 is long range, high energy beta emitter and Bismuth-212 a short range alpha emitter. Based on these studies, a successful Phase I trial of treatment of Adult T-cell Leukemia has been completed. A phase II trial is now underway. The compound cyclohexyl DTPA was recently tested and used for radioimmunotherapy of the Rauscher leukemia in mice. Efficacy was exceptional in that complete remission of disease was induced with no histological evidence of toxicity. Studies like these are providing for human medicine a basis for design of rational therapies of malignancies by selectively targeting cytocidal agents to tumors, as well as metastases and will in addition allow improved diagnostic imaging of malignancies.

肿瘤相关单克隆抗体是潜在的治疗药物